Vitamin B12

Vitamin B12 at a Glance

Vitamin B12 (cobalamin) is a cobalt-containing vitamin made by bacteria rather than by plants or animals, which is why it reaches us almost entirely through animal foods.

Its distinctive feature is the machinery required to absorb it: intrinsic factor, a protein made by the stomach, plus a dedicated receptor in the terminal ileum. That makes B12 status as much a question of absorption as of intake, and it is why deficiency shows up with age, after gastric surgery, and on long-term metformin or acid-suppressing drugs.

What It’s Used For

Correcting deficiency & pernicious anemia — its core use, restoring red-cell production and energy.
Deficiency-related neuropathy — repairs the nerve damage deficiency causes.
Cognitive decline in high-homocysteine MCI — used where homocysteine is raised and cognition is declining.
Depression (adjunct, long-term) — a long-term adjunct for mood.

How It Works

B12 is a cofactor for exactly two human enzymes. Methionine synthase converts homocysteine to methionine, feeding the methylation cycle that builds DNA and myelin — which is why deficiency produces both anemia and nerve damage. Methylmalonyl-CoA mutase handles branched-chain fats; when it stalls, methylmalonic acid accumulates, and that is the most specific marker of true deficiency.

Because normal absorption is receptor-limited, high-dose oral B12 works even in pernicious anemia — roughly 1% crosses by passive diffusion, which at 1,000 µg is enough.

The full trial record is in Pharmacology & Research below.

Pharmacology & Research

Vitamin B12 (cobalamin) is a water-soluble, cobalt-containing B vitamin that acts as an obligatory cofactor for two enzymes — methionine synthase and methylmalonyl-CoA mutase — and its clinical story is overwhelmingly a story of deficiency correction, not of extra benefit layered on top of an adequate diet. Where a person is genuinely low (vegans, older adults with atrophic gastritis, people on metformin or with pernicious anemia), repletion is one of the more reliably effective interventions in nutrition, and — importantly — high-dose oral B12 works about as well as injections for most people ^{1,2Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}.

Where a person is already replete, the evidence for the popular uses — energy, mood, general cognition — is thin to null ^{11Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →}.

Form matters less than marketing suggests: cyanocobalamin, methylcobalamin, hydroxocobalamin and adenosylcobalamin are largely interchangeable vitamers once absorbed, and fractional absorption is capped by intrinsic factor (~1.5–2 mcg per dose), which is precisely why corrective regimens use hundreds to thousands of micrograms.

Best-supported:Correcting established B12 deficiency and pernicious anemia — and doing it with high-dose oral B12 rather than injections, which normalizes serum levels and blood counts equally well at far lower cost ^{1,2,3Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →Reference 3Yajnik et al. · 2019A physiological dose of oral vitamin B-12 improves haematological, biochemical and nerve-function indices — [intervention trial]View study →}.

Emerging / cautiously endorsed:Improving nerve-conduction measures and symptoms in deficiency-related peripheral and diabetic neuropathy ^{4,5,6Reference 4Didangelos et al. · 2021RCTVitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial — [RCT]View study →Reference 5Sawangjit et al. · 2020Meta-analysisEfficacy and safety of mecobalamin on peripheral neuropathy: systematic review and meta-analysis of RCTs — [meta-analysis]View study →Reference 6Mansour et al. · 2026RCTOral vitamin B-12 1000 μg vs 2000 μg on neuropathic outcomes in diabetic peripheral neuropathy — [RCT]View study →}; slowing brain atrophy and cognitive decline specifically in older people with mild cognitive impairment and elevated homocysteine (VITACOG) ^{7,8,9Reference 7Smith et al. · 2010RCTHomocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG) — [RCT]View study →Reference 8de Jager et al. · 2012RCTCognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment — [RCT]View study →Reference 9Douaud et al. · 2013RCTPreventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment — [RCT, imaging]View study →}.

Popular but thin / overhyped:“Energy” and anti-fatigue use in people who are not deficient; mood/depression benefit as a standalone treatment — both rest on weak or null trials ^{10,11,12Reference 10Clarke et al. · 2014Meta-analysisEffects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]View study →Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →Reference 12Almeida et al. · 2015Meta-analysisSystematic review and meta-analysis of RCTs of folate and vitamin B12 for depression — [meta-analysis]View study →}.

The honest miss / caveat:B12 (with folate) reliably lowers homocysteine by ~25–30% ^{13Reference 13Homocysteine Lowering Trialists’ Collabo · 1998Meta-analysisLowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials — [meta-analysis]View study →}, but the large cardiovascular and general-cognition trials that lowered homocysteine found no reduction in heart attacks, strokes overall, or cognitive decline in unselected populations ^{10,14Reference 10Clarke et al. · 2014Meta-analysisEffects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]View study →Reference 14Clarke et al. · 2010Meta-analysisEffects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer and cause-specific mortality: meta-analysis of 8 trials, 37,485 individuals — [meta-analysis]View study →}. The biomarker moves; the hard outcomes mostly do not — the one partial exception is stroke, where folic acid (not B12) modestly reduces risk specifically in regions without grain fortification ^{16Reference 16Zhao et al. · 2017Meta-analysisMeta-analysis of folic acid efficacy trials in stroke prevention: insight into effect modifiers — [meta-analysis]View study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

The VITACOG trial (266 older adults with mild cognitive impairment) gave a B-vitamin combination (folic acid 0.8 mg, B12 0.5 mg, B6 20 mg) for 2 years. It lowered homocysteine ~30%, slowed whole-brain atrophy, and — in the pre-specified subgroup with baseline homocysteine above the median — stabilized executive function, global cognition and memory ^{7,8Reference 7Smith et al. · 2010RCTHomocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG) — [RCT]View study →Reference 8de Jager et al. · 2012RCTCognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment — [RCT]View study →}.

A follow-on imaging analysis reported up to a seven-fold reduction in atrophy of Alzheimer-vulnerable gray-matter regions, confined to the high-homocysteine participants ^{9Reference 9Douaud et al. · 2013RCTPreventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment — [RCT, imaging]View study →}.

But this is one center’s combination-therapy result, and it does not generalize: a meta-analysis of 11 trials in 22,000 people found homocysteine lowering had no effect on cognitive aging (z-score difference 0.00), and a B12-specific meta-analysis found no cognitive benefit in people without deficiency ^{10,11Reference 10Clarke et al. · 2014Meta-analysisEffects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]View study →Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →}.

A larger synthesis (95 studies) reported a small MMSE benefit from B vitamins overall but found that lower folate — not B12 or B6 — drove the association with dementia risk, reinforcing that any cognitive effect here is folate-led, not a B12 story ^{15Reference 15Wang et al. · 2022Meta-analysisB vitamins and prevention of cognitive decline and incident dementia: a systematic review and meta-analysis — [meta-analysis]View study →}.

Gap: The effect is a combination (folate-led) effect seen only in elevated-homocysteine MCI, not a general B12 cognitive benefit; the positive trial’s senior authors hold patents on B-vitamin treatment of cognitive impairment, and independent replication at scale is still lacking ^{9,10Reference 9Douaud et al. · 2013RCTPreventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment — [RCT, imaging]View study →Reference 10Clarke et al. · 2014Meta-analysisEffects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]View study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Methionine synthase (cytosol)	Cofactor; remethylates homocysteine → methionine (with 5-MTHF folate)	Homocysteine lowering; DNA methylation; folate “trap” when B12 low
Methylmalonyl-CoA mutase (mitochondria)	Cofactor; converts methylmalonyl-CoA → succinyl-CoA	Fatty-acid/amino-acid catabolism; MMA rises when B12 low (deficiency marker)
Myelin maintenance	Downstream of the two enzyme roles	Neuropathy; subacute combined degeneration
Erythropoiesis / DNA synthesis	Thymidylate supply via folate cycle	Megaloblastic anemia in deficiency

Pharmacokinetics

Dietary B12 is released from food protein by gastric acid/pepsin, bound to intrinsic factor (secreted by gastric parietal cells) and absorbed in the terminal ileum. This receptor-mediated route is saturable at ~1.5–2 mcg per meal, so absorption efficiency falls sharply as dose rises — a single large dose is mostly wasted through that channel. However, roughly 1% of any oral dose is absorbed by passive diffusion independent of intrinsic factor, which is why 1,000–2,000 mcg/day oral tablets can treat pernicious anemia despite the absence of intrinsic factor ^{1,2Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}. The body stores 2–5 mg (mostly hepatic), enough for several years, so deficiency develops slowly and, once corrected, is slow to recur. Excess is renally excreted, underpinning the low toxicity. Serum B12 is an imperfect marker; methylmalonic acid and homocysteine are more sensitive functional indicators of deficiency.

Clinical trials

B12 is off-patent and cheap, so most modern trial activity is combination B-vitamin work (cardiovascular, cognitive) or deficiency-repletion and neuropathy studies out of Asia and Europe rather than industry-driven programs; registered activity continues, principally in diabetic neuropathy and cognitive aging.

Completed	Planned	Terminated	Preclinical
~40+(repletion, neuropathy, homocysteine/cognition)	Several(DPN, cognitive aging)	Few	~100s (mechanistic)

Last checked: July 2026.

Dietary Sources

Vitamin B12 is synthesized only by microorganisms; it enters the human diet almost exclusively through animal foods, where it has accumulated up the food chain. Plant foods contain essentially none — so people avoiding animal products depend on fortified foods (some breakfast cereals, nutritional yeast) or supplements. Absorption from food is limited by intrinsic factor to roughly 1.5–2 mcg per meal regardless of how much the food contains, and up to 10–30% of older adults cannot liberate B12 from food protein efficiently (food-cobalamin malabsorption) even while absorbing the crystalline form in supplements and fortified foods normally.

Food (typical serving)	Approx. B12	Notes
Clams (3 oz)	~84 mcg	Richest common source
Beef liver (3 oz)	~70 mcg	Very high
Trout / salmon (3 oz)	~3–5 mcg	Also omega-3s
Tuna, beef (3 oz)	~2.5 mcg	—
Milk / yoghurt (1 cup)	~1.2–1.4 mcg	Well absorbed
Egg (1 large)	~0.5 mcg	Lower bioavailability
Fortified cereal / nutritional yeast	~0.6–6 mcg	The reliable plant-based route (crystalline B12)

Amounts per the NIH Office of Dietary Supplements Vitamin B12 fact sheet. The main dietary risk factor is simply avoiding animal foods without fortification.

Dosage & Intake

RDA (adults): 2.4 mcg/day; pregnancy 2.6 mcg; lactation 2.8 mcg (IOM Dietary Reference Intakes).
Upper limit: None established. B12 has very low toxicity and no UL — but “no UL” reflects lack of observed harm, not evidence that any dose is beneficial.
Correcting deficiency: oral 1,000–2,000 mcg/day normalizes status as effectively as intramuscular injection for most people, including many with pernicious anemia, because ~1% is absorbed passively ^{1,2Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}. Injections (hydroxocobalamin, 1,000 mcg) remain standard where malabsorption is severe or neurological signs are present.
Form: cyanocobalamin (most stable/cheapest), methylcobalamin, hydroxocobalamin and adenosylcobalamin are effectively interchangeable vitamers once absorbed — the body interconverts them. No convincing trial shows a clinically meaningful advantage of “active” methylcobalamin over cyanocobalamin for correcting deficiency, though cyanocobalamin is theoretically avoided in rare hereditary optic neuropathy and severe renal impairment.
Because it is not a weight-based mineral, “elemental” adjustments do not apply — B12 is dosed directly in micrograms.

These are doses studied in research, not a personal recommendation.

Safety

Vitamin B12 is among the safest vitamins — the body excretes what it cannot store and no upper limit has been set. The real issues are interpretive and interactional, not toxic: several common drugs deplete it, and a high serum level in someone not supplementing is a signal to investigate, not to relax.

Safety at a Glance

Low / no toxicityDrug interactions

Very low toxicity, no Tolerable Upper Intake Level. Corrective doses of hundreds to a thousand-plus micrograms are used freely.
Recommended in pregnancy and lactation. Needs rise modestly and routine supplemental doses are considered safe — see the box below.
Several drugs deplete B12. Metformin, proton-pump inhibitors and H2 blockers reduce absorption over the long term; nitrous oxide can precipitate acute deficiency.
High-dose folic acid can mask B12 deficiency. The anemia resolves while neurological damage progresses — check B12 before treating with folate.
An elevated serum B12 without supplementation warrants investigation. It can mark underlying liver or hematological disease.
Avoid cyanocobalamin with hereditary Leber optic neuropathy. And do not switch from injections to oral without monitoring if neurological signs are present.

Full Safety & Interactions Detail

Vitamin B12 is among the safest vitamins: the body excretes what it cannot store, and no Tolerable Upper Intake Level has been established, so corrective doses of hundreds to a thousand-plus micrograms are used freely ^{1Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →}.

Reported adverse effects are uncommon and mild — occasional acneiform or rosacea-like skin eruptions with high-dose supplementation. A more important clinical caveat is interpretive: an elevated serum B12 in someone not supplementing can be a marker of underlying liver or hematological disease and warrants investigation rather than reassurance.

Interactions (drug classes checked): Metformin lowers B12 absorption with long-term use (screen/supplement diabetics). Proton-pump inhibitors and H2 blockers reduce acid-dependent release of food B12 over years. Nitrous oxide irreversibly inactivates B12 and can precipitate acute deficiency in those with marginal stores. High-dose folic acid can mask the anemia of B12 deficiency while neurological damage progresses — a longstanding reason to check B12 before treating with folate.

Who should be cautious: people relying on injections due to malabsorption should not switch to oral without monitoring if neurological signs are present; those with hereditary Leber optic neuropathy should avoid cyanocobalamin.

Scope of this safety review (for honesty, not a claim):

Interactions assessed? Yes — metformin, acid-suppressing drugs (PPIs/H2 blockers), nitrous oxide, and folic-acid masking were reviewed.
Pregnancy/lactation assessed? Yes — increased need in pregnancy/lactation and infant risk from maternal deficiency.
Upper Limit? No UL set by the IOM. This reflects low observed toxicity, not evidence that megadoses are beneficial — do not infer that unlimited intake is useful or risk-free.

Pregnancy & Lactation

Safe in pregnancy Safe while breastfeeding

Verdict: recommended at RDA levels; supplementation is important for those at risk. B12 needs rise modestly in pregnancy (2.6 mcg) and lactation (2.8 mcg), and maternal deficiency — particularly in vegan or vegetarian mothers — can cause serious neurological harm in exclusively breastfed infants. Routine supplemental doses are considered safe; there is no evidence of harm from typical prenatal amounts.

References

Wang, H., Li, L., Qin, L. L., Song, Y., Vidal-Alaball, J., & Liu, T. H. (2018). Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/29543316/
Lederle, F. A. (1998). Oral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]. Journal of the American Geriatrics Society. https://pubmed.ncbi.nlm.nih.gov/9736106/
Yajnik, C. S., Behere, R. V., Bhat, D. S., et al. (2019). A physiological dose of oral vitamin B-12 improves haematological, biochemical and nerve-function indices — [intervention trial]. PLoS One. https://pubmed.ncbi.nlm.nih.gov/31600243/
Didangelos, T., Karlafti, E., Kotzakioulafi, E., et al. (2021). Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial — [RCT]. Nutrients. https://pubmed.ncbi.nlm.nih.gov/33513879/
Sawangjit, R., Thongphui, S., Chaichompu, W., & Phumart, P. (2020). Efficacy and safety of mecobalamin on peripheral neuropathy: systematic review and meta-analysis of RCTs — [meta-analysis]. Journal of Alternative and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/32716261/
Mansour, A., Amrollahi Bioky, A., Gerami, H., et al. (2026). Oral vitamin B-12 1000 μg vs 2000 μg on neuropathic outcomes in diabetic peripheral neuropathy — [RCT]. Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/41548600/
Smith, A. D., Smith, S. M., de Jager, C. A., et al. (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG) — [RCT]. PLoS One. https://pubmed.ncbi.nlm.nih.gov/20838622/
de Jager, C. A., Oulhaj, A., Jacoby, R., Refsum, H., & Smith, A. D. (2012). Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment — [RCT]. International Journal of Geriatric Psychiatry. https://pubmed.ncbi.nlm.nih.gov/21780182/
Douaud, G., Refsum, H., de Jager, C. A., et al. (2013). Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment — [RCT, imaging]. Proceedings of the National Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/23690582/
Clarke, R., Bennett, D., Parish, S., et al.; B-Vitamin Treatment Trialists’ Collaboration. (2014). Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/24965307/
Markun, S., Gravestock, I., Jäger, L., et al. (2021). Effects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]. Nutrients. https://pubmed.ncbi.nlm.nih.gov/33809274/
Almeida, O. P., Ford, A. H., & Flicker, L. (2015). Systematic review and meta-analysis of RCTs of folate and vitamin B12 for depression — [meta-analysis]. International Psychogeriatrics. https://pubmed.ncbi.nlm.nih.gov/25644193/
Homocysteine Lowering Trialists’ Collaboration. (1998). Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials — [meta-analysis]. BMJ. https://pubmed.ncbi.nlm.nih.gov/9569395/
Clarke, R., Halsey, J., Lewington, S., et al.; B-Vitamin Treatment Trialists’ Collaboration. (2010). Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer and cause-specific mortality: meta-analysis of 8 trials, 37,485 individuals — [meta-analysis]. Archives of Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/20937919/
Wang, Z., Zhu, W., Xing, Y., Jia, J., & Tang, Y. (2022). B vitamins and prevention of cognitive decline and incident dementia: a systematic review and meta-analysis — [meta-analysis]. Nutrition Reviews. https://pubmed.ncbi.nlm.nih.gov/34432056/
Zhao, M., Wu, G., Li, Y., et al. (2017). Meta-analysis of folic acid efficacy trials in stroke prevention: insight into effect modifiers — [meta-analysis]. Neurology. https://pubmed.ncbi.nlm.nih.gov/28404799/